While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

We recently compiled a list of the 13 Cheap High Dividend Stocks To Invest In Now. In this article, we are going to take a ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...